Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium

Annegien Broeks(American Physical Therapy Association), Marjanka K. Schmidt(American Physical Therapy Association), Mark E. Sherman(National Cancer Institute), Fergus J. Couch(Mayo Clinic in Florida), John L. Hopper, Gillian S. Dite, Carmel Apicella, Letitia Smith(The University of Melbourne), Fleur Hammet(The University of Melbourne), Melissa C. Southey(The University of Melbourne), Laura van ‘t Veer(American Physical Therapy Association), Renate H. M. de Groot(The Netherlands Cancer Institute), Vincent T.H.B.M. Smit(Leiden University), Peter A. Fasching(University of California, Los Angeles), Matthias W. Beckmann, Sebastian M. Jud, Arif B. Ekici(Friedrich-Alexander-Universität Erlangen-Nürnberg), Arndt Hartmann(Taipei Institute of Pathology), Alexander Hein, R. Schulz-Wendtland(Universitätsklinikum Erlangen), Barbara Burwinkel, Frederik Marmé, Andreas Schneeweiß, Hans‐Peter Sinn(Heidelberg University), Christof Sohn, Sandrine Tchatchou, Stig E. Bojesen(University of Copenhagen), Børge G. Nordestgaard(University of Copenhagen), Henrik Flyger(University of Copenhagen), David D. Ørsted(University of Copenhagen), Diljit Kaur‐Knudsen(University of Copenhagen), Roger L. Milne, José Ignacio Arias Pérez, Pilar Zamora(Hospital Universitario La Paz), Primitiva Menéndez Rodríguez(Hospital Monte Naranco), Javier Benı́tez(Spanish National Cancer Research Centre), Hiltrud Brauch(Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology), Christina Justenhoven(Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology), Yon‐Dschun Ko(Johanniter-Krankenhaus Bonn), The Genica Network(German Cancer Research Center), Ute Hamann(University of Bonn), Hans‐Peter Fischer(University of Bonn), Thomas Brüning(Institute for Prevention and Occupational Medicine), Beate Pesch(German Cancer Research Center), Jenny Chang‐Claude(German Cancer Research Center), Shan Wang‐Gohrke(Universität Ulm), Michael Bremer(Medizinische Hochschule Hannover), Johann H. Karstens(Medizinische Hochschule Hannover), Peter Hillemanns(Medizinische Hochschule Hannover), Thilo Dörk(Medizinische Hochschule Hannover), Heli Nevanlinna, Tuomas Heikkinen, Päivi Heikkilä(Helsinki University Hospital), Carl Blomqvist(Helsinki University Hospital), Kristiina Aittomäki(Helsinki University Hospital), Kirsimari Aaltonen(Helsinki University Hospital), Annika Lindblom, Sara Margolin(University of Eastern Finland), Arto Mannermaa(University of Eastern Finland), Veli‐Matti Kosma(University of Eastern Finland), Jaana M. Kauppinen(University of Eastern Finland), Vesa Kataja(Vaasa Central Hospital), Päivi Auvinen(Kuopio University Hospital), Matti Eskelinen(University of Eastern Finland), Ylermi Soini(University of Eastern Finland), Georgia Chenevix‐Trench(QIMR Berghofer Medical Research Institute), Amanda B. Spurdle(QIMR Berghofer Medical Research Institute), Jonathan Beesley(QIMR Berghofer Medical Research Institute), Xiaoqing Chen(QIMR Berghofer Medical Research Institute), Helene Holland(QIMR Berghofer Medical Research Institute), kConFab(VIB-KU Leuven Center for Microbiology), AOCS, Diether Lambrechts(VIB-KU Leuven Center for Microbiology), Bart Claes(VIB-KU Leuven Center for Microbiology), T. Vandorpe(Universität Hamburg), Patrick Neven(German Cancer Research Center), Hans Wildiers(Albertinen Diakoniewerk), Dieter Flesch‐Janys(Universität Hamburg), Rebecca Hein(German Cancer Research Center), Thomas Löning(Albertinen Diakoniewerk), Matthew Kosel(Cancer Council Victoria), Zachary S. Fredericksen(The Alfred Hospital), Xianshu Wang(Cancer Council Victoria), Graham G. Giles(Cancer Council Victoria), Laura Baglietto(University of Southern California), Gianluca Severi(University of Southern California), Catriona McLean(University of Hawaiʻi at Mānoa), Christopher A. Haiman(University of Southern California), Brian E. Henderson(University of Southern California), Loı̈c Le Marchand(University of Hawaiʻi at Mānoa), Laurence N. Kolonel(University of Hawaiʻi at Mānoa), Grethe Grenaker Alnæs(Oslo University Hospital), Vessela Kristensen(Oslo University Hospital), Anne‐Lise Børresen‐Dale(Oslo University Hospital), David J. Hunter(Brigham and Women's Hospital), Susan E. Hankinson(Brigham and Women's Hospital), Irene L. Andrulis(Mount Sinai Hospital), Anna Marie Mulligan(St. Michael's Hospital), Frances P. O’Malley(St. Michael's Hospital), Peter Devilee, Petra E.A. Huijts(Erasmus MC Cancer Institute), Rob A.�E.�M. Tollenaar(Leiden University Medical Center), Christi J. van Asperen(The Maria Sklodowska-Curie National Research Institute of Oncology), Caroline Seynaeve(National Cancer Institute), Stephen J. Chanock(Nofer Institute of Occupational Medicine), Jolanta Lissowska(National Cancer Institute), Louise A. Brinton(National Cancer Institute), Beata Pepłońska(Nofer Institute of Occupational Medicine), Jonine D. Figueroa(National Cancer Institute), Xiaohong R. Yang(National Cancer Institute), Maartje J. Hooning, Antoinette Hollestelle, Rogier A. Oldenburg, Agnes Jager(Erasmus MC), Mieke Kriege(Karolinska Institutet), Bahar Ozturk(Karolinska Institutet), Geert J.L.H. van Leenders(Erasmus MC), Per Hall(Karolinska Institutet), Kamila Czene(Karolinska Institutet), Keith Humphreys(Karolinska Institutet), Jianjun Liu(Genome Institute of Singapore), Angela Cox, Daniel Connley(University of Sheffield), Helen Cramp(University of Sheffield), Simon S. Cross, Sabapathy P. Balasubramanian(University of Cambridge), Malcolm Reed(University of Cambridge), Alison M. Dunning, Douglas F. Easton(University of Cambridge), Manjeet K. Humphreys(University of Cambridge), Carlos Caldas, Fiona M. Blows(International Hereditary Cancer Center), Kristy Driver(International Hereditary Cancer Center), Elena Provenzano(International Hereditary Cancer Center), Jan Lubiński(International Hereditary Cancer Center), Anna Jakubowska(International Hereditary Cancer Center), Tomasz Huzarski(International Hereditary Cancer Center), Tomasz Byrski(International Hereditary Cancer Center), Cezary Cybulski(International Hereditary Cancer Center), Bohdan Górski(National Cancer Institute of Thailand), Jacek Gronwald(International Hereditary Cancer Center), Paul Brennan(China Medical University), Suleeporn Sangrajrang(Institute of Biomedical Sciences, Academia Sinica), Valérie Gaborieau(Centre international de recherche sur le cancer), Chen‐Yang Shen(China Medical University), Chia‐Ni Hsiung(Tri-Service General Hospital), Jyh‐Cherng Yu(Kaohsiung Medical University), Shou‐Tung Chen(National Taiwan University Hospital), Giu‐Cheng Hsu(Tri-Service General Hospital), Ming‐Feng Hou(Kaohsiung Medical University), Chiun‐Sheng Huang(University of Cambridge), Hoda Anton‐Culver(University of California, Irvine), Argyrios Ziogas(University of California, Irvine), Paul D.P. Pharoah(University of Cambridge), Montserrat García‐Closas(University of Cambridge)
Human Molecular Genetics
May 19, 2011
Cited by 173Open Access
Full Text

Abstract

Breast cancers demonstrate substantial biological, clinical and etiological heterogeneity. We investigated breast cancer risk associations of eight susceptibility loci identified in GWAS and two putative susceptibility loci in candidate genes in relation to specific breast tumor subtypes. Subtypes were defined by five markers (ER, PR, HER2, CK5/6, EGFR) and other pathological and clinical features. Analyses included up to 30 040 invasive breast cancer cases and 53 692 controls from 31 studies within the Breast Cancer Association Consortium. We confirmed previous reports of stronger associations with ER+ than ER- tumors for six of the eight loci identified in GWAS: rs2981582 (10q26) (P-heterogeneity = 6.1 × 10(-18)), rs3803662 (16q12) (P = 3.7 × 10(-5)), rs13281615 (8q24) (P = 0.002), rs13387042 (2q35) (P = 0.006), rs4973768 (3p24) (P = 0.003) and rs6504950 (17q23) (P = 0.002). The two candidate loci, CASP8 (rs1045485, rs17468277) and TGFB1 (rs1982073), were most strongly related with the risk of PR negative tumors (P = 5.1 × 10(-6) and P = 4.1 × 10(-4), respectively), as previously suggested. Four of the eight loci identified in GWAS were associated with triple negative tumors (P ≤ 0.016): rs3803662 (16q12), rs889312 (5q11), rs3817198 (11p15) and rs13387042 (2q35); however, only two of them (16q12 and 2q35) were associated with tumors with the core basal phenotype (P ≤ 0.002). These analyses are consistent with different biological origins of breast cancers, and indicate that tumor stratification might help in the identification and characterization of novel risk factors for breast cancer subtypes. This may eventually result in further improvements in prevention, early detection and treatment.


Related Papers

No related papers found

Powered by citation graph analysis